ArticleLancet regional health. Americas2026
Implementation of AESOP early-warning system for respiratory disease: a pilot and validation study using routinely collected data in Amazonas, Brazil.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory infections cause major morbidity and mortality globally, highlighting the need for robust early-warning systems (EWS). The Alert-Early System of Outbreaks with Pandemic Potential (ÆSOP) was co-developed with surveillance stakeholders to detect outbreaks using administrative primary health care (PHC) data. We aimed to report ÆSOP's feasibility and performance for detecting influenza-like illness (ILI) outbreaks in a real-world context and to document lessons learned from translating research into routine health services. Methods: The pilot was conducted in Amazonas, Brazil, from April to July 2024, covering 62 municipalities. ÆSOP relies on anomaly detection models applied to weekly counts of ILI-related PHC encounters, and municipal-level warnings are issued when thresholds are exceeded. Local health authorities validated warnings through a structured questionnaire. Performance was evaluated by sensitivity, specificity, positive and negative predictive value (PPV and NPV). Findings: During the study period, 1.8 million PHC encounters were reported, of which 6.6% were ILI-related. ÆSOP issued 104 warnings across 41 municipalities. Sensitivity was 62.8% (95% CI 54.4%-70.5%), specificity 95.5% (95% CI 93.1%-97.1%), PPV 82.7%, (95% CI 74.3%-88.8%), and NPV 88.1% (95% CI 84.7%-90.9%). In 72% of confirmed outbreaks, ÆSOP provided the first signal to authorities, and in 56%, warnings supported responses including enhanced risk communication, equipment/test deployment, and strengthening of intergovernmental coordination. Interpretation: ÆSOP anticipated outbreaks in real-world usage and was validated by authorities as a decision-support tool. Its reliance on administrative data and open-source technologies enhances scalability and adaptability across health systems globally. Funding: Rockefeller Foundation (award 2023 PPI 007).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.